All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

Lilly’s Omvoh benefit continues for four years in UC

Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown continued benefit after four years in a Phase III open-label extension trial in patients…
FDA lifts clinical hold on Neurizon’s ALS drug

The US Food and Drug Administration (FDA) has released its clinical hold on Neurizon Therapeutics’ NUZ‑001, paving the way for…
Amgen’s Phase III data supports FDA label expansion of Repatha

Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug…
Pfizer shakes hands with White House on drug discounts under MFN programme

Pfizer is the first in what could be a string of pharmaceutical companies to come to an agreement with the…
Podcast: How oral GLP-1RAs are set to impact the obesity market

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have taken the weight-loss world by storm. Even beyond the healthcare world, Ozempic, Wegovy and…

Can oral GLP-1RAs deliver on the promise of accessible obesity care?

As the race for oral glucagon-like peptide-1 receptor agonists (GLP-1RA) intensifies, physicians hope that their small molecule format will make…
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail

aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary…
Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage

Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia…
ESC 2025: Novo Nordisk’s Wegovy superior to Zepbound in reducing CV events

Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA) Wegovy (semaglutide) showed a significant reduction in cardiovascular (CV) events compared to Eli…
Epkinly breaks ground in Phase III FL trial

Genmab and AbbVie’s subcutaneous bispecific antibody Epkinly (epcoritamab) has met its dual primary endpoints as a second-line combination therapy in…